Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences
Kodiak Sciences announced that KSI-101 data from an Asian tertiary care uveitis cohort demonstrated outcomes consistent with the U.S. Phase 1b APEX study, supporting global expansion of Phase 3 programs. In the Asian cohort, 58% of patients achieved a ≥15-letter gain in BCVA with a mean increase of +17.8 letters at Week 24, and central subfield thickness was reduced to <325 µm after a single injection.
Key figures
- Drug Name
- KSI-101
- Phase Of Trial
- Phase 1b
- Cst reduction threshold um
- <325 µm
- Irf srf resolution percent
- >90%
- Mean bcva increase letters
- +17.8
- Patients gain 15 plus percent
- 58%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.